INmune Bio, Inc. (INMB) 10-Year Financial Performance & Capital Metrics

INMB • • Industrial / General

HealthcareBiotechnologyOncology TherapeuticsImmuno-Oncology

AboutINmune Bio, Inc., a clinical-stage immunotherapy company, focuses on developing drugs to reprogram the patient's innate immune system to treat disease. The company develops and commercializes product candidates to treat hematologic malignancies, solid tumors, and chronic inflammation. Its development programs include INKmune, which focuses on treating women with relapse refractory ovarian carcinoma and patients with high-risk myelodysplastic syndrome; INB03, an immunotherapy that treats patients with hematologic malignancies and solid tumors; and XPro1595 for the treatment of Alzheimer's disease. The company has license agreements with Xencor, Inc.; Immune Ventures, LLC; University of Pittsburg; and University College London. INmune Bio, Inc. was incorporated in 2015 and is headquartered in Boca Raton, Florida.Show more

Revenue $14K -91.0%
EBITDA -$42M
Net Income -$42M -40.2%
EPS (Diluted) -2.11 -26.3%
Gross Margin 100%
EBITDA Margin -300585.71%
Operating Margin -304535.71% -1487.1%
Net Margin -300585.71% -1452.6%
ROE -119.83% -96.2%
ROIC -263.32% -112.4%
Debt/Equity 0.01 -95.6%
Interest Coverage -

Technical Analysis

Key Insights

Based on financial data analysis

✓Strengths

✓Company is almost debt free
✓Trading at only 1.0x book value

✗Weaknesses

✗Weak Piotroski F-Score: 3/9
✗Negative free cash flow
✗Weak momentum: RS Rating 11 (bottom 11%)
✗Shares diluted 10.9% in last year
✗Trading more than 30% below 52-week high
✗Low asset turnover indicates capital-intensive operations

Price & Volume

Loading chart...

Growth Metrics

Revenue CAGR

10Y-

5Y-

3Y-57.39%

TTM19.05%

Profit (Net Income) CAGR

10Y-

5Y-

3Y-

TTM-20.87%

EPS CAGR

10Y-

5Y-

3Y-

TTM2.29%

ROCE

10Y Avg-178.77%

5Y Avg-57.65%

3Y Avg-68.62%

Latest-120.31%

Peer Comparison

Immuno-Oncology

Name	Market Cap	Current Price	P/E Ratio	Revenue Growth 1Y	Net Margin	ROE	Debt/Equity
IMTXImmatics N.V.	1.33B	9.92	70.86	188.6%	-136.72%	-27.81%	0.03
CTMXCytomX Therapeutics, Inc.	720.1M	4.25	11.18	36.45%	24.66%	26.09%
IOVAIovance Biotherapeutics, Inc.	881.27M	2.22	-1.73	136.99%	-158.78%	-56.62%	0.08
REPLReplimune Group, Inc.	572.64M	7.30	-2.38			-117.82%	0.18
NKTRNektar Therapeutics	719.28M	35.36	-4.07	9.22%	-192.87%	-141.9%	1.69
IMNMImmunome, Inc.	2.52B	22.85	-4.57	-35.5%	-23.01%	-84.4%	0.03
IBRXImmunityBio, Inc.	3.89B	3.95	-6.37	22.71%	-422.28%
NRIXNurix Therapeutics, Inc.	1.91B	18.86	-6.55	-29.15%	-292.5%	-65.76%	0.05

Profit & Loss

	Dec 2015	Dec 2016	Dec 2017	Dec 2018	Dec 2019	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024
Sales/Revenue+	0	0	0	0	0	11K	181K	374K	155K	14K
Revenue Growth %	-	-	-	-	-	-	15.45%	1.07%	-0.59%	-0.91%
Cost of Goods Sold+	0	0	0	0	0	0	0	0	0	0
COGS % of Revenue	-	-	-	-	-	-	-	-	-	-
Gross Profit+	0	0	0	0	0	11K	181K	374K	155K	14K
Gross Margin %	-	-	-	-	-	1%	1%	1%	1%	1%
Gross Profit Growth %	-	-	-	-	-	-	15.45%	1.07%	-0.59%	-0.91%
Operating Expenses+	48.87K	227.49K	981.48K	12.44M	7.76M	12.24M	29.33M	26.32M	29.9M	42.65M
OpEx % of Revenue	-	-	-	-	-	1112.64%	162.07%	70.39%	192.88%	3046.36%
Selling, General & Admin	48.87K	126K	546.12K	9.09M	4.47M	6.32M	8.79M	9.26M	9.62M	9.48M
SG&A % of Revenue	-	-	-	-	-	574.64%	48.57%	24.75%	62.08%	677.36%
Research & Development	0	101.5K	435.36K	1.1M	3.28M	5.92M	20.54M	17.07M	20.27M	33.17M
R&D % of Revenue	-	-	-	-	-	537.91%	113.5%	45.63%	130.79%	2369%
Other Operating Expenses	0	0	-6	0	0	1K	0	0	0	0
Operating Income+	-48.87K	-227K	-981K	-12.44M	-7.76M	-12.23M	-29.15M	-25.95M	-29.74M	-42.63M
Operating Margin %	-	-	-	-	-	-1111.64%	-161.07%	-69.39%	-191.88%	-3045.36%
Operating Income Growth %	-	-3.65%	-3.32%	-11.68%	0.38%	-0.58%	-1.38%	0.11%	-0.15%	-0.43%
EBITDA+	146.6K	491	480	0	-7.68M	0	0	0	0	-42.08M
EBITDA Margin %	-	-	-	-	-	-	-	-	-	-3005.86%
EBITDA Growth %	-	-1%	-0.02%	-1%	-	1%	-	-	-	-
D&A (Non-Cash Add-back)	195.47K	227.49K	981.48K	12.44M	0	12.23M	29.15M	25.95M	29.74M	553K
EBIT	-48.87K	-277K	-831K	-12.44M	-7.68M	-12.23M	-29.15M	-25.95M	-29.74M	-42.63M
Net Interest Income+	0	0	0	0	77.69K	0	0	-2.01M	0	0
Interest Income	0	0	0	0	77.69K	0	0	0	0	0
Interest Expense	0	0	0	0	0	0	0	1.35M	0	0
Other Income/Expense	0	-50K	149.99K	0	77.69K	129K	-1.19M	-1.35M	-267K	553K
Pretax Income+	-48.87K	-277K	-831K	-12.44M	-7.68M	-12.1M	-30.34M	-27.3M	-30.01M	-42.08M
Pretax Margin %	-	-	-	-	-	-1099.91%	-167.62%	-72.99%	-193.6%	-3005.86%
Income Tax+	0	0	0	0	0	0	0	0	0	0
Effective Tax Rate %	1%	1%	1%	1%	1%	1%	1%	1%	1%	1%
Net Income+	-48.87K	-277K	-831K	-12.44M	-7.68M	-12.1M	-30.34M	-27.3M	-30.01M	-42.08M
Net Margin %	-	-	-	-	-	-1099.91%	-167.62%	-72.99%	-193.6%	-3005.86%
Net Income Growth %	-	-4.67%	-2%	-13.97%	0.38%	-0.58%	-1.51%	0.1%	-0.1%	-0.4%
Net Income (Continuing)	-48.87K	-277K	-831K	-12.44M	-7.68M	-12.1M	-30.34M	-27.3M	-30.01M	-42.08M
Discontinued Operations	0	0	0	0	0	0	0	0	0	0
Minority Interest	0	0	0	0	0	0	0	0	0	0
EPS (Diluted)+	-0.01	-0.05	-0.07	-1.11	-0.89	-1.01	-1.88	-1.52	-1.67	-2.11
EPS Growth %	-	-	-0.37%	-13.98%	0.2%	-0.13%	-0.86%	0.19%	-0.1%	-0.26%
EPS (Basic)	-0.01	-0.05	-0.07	-1.11	-0.89	-1.01	-1.88	-1.52	-1.67	-2.11
Diluted Shares Outstanding	5M	5.11M	11.22M	11.22M	10.27M	11.99M	16.13M	17.93M	17.98M	19.94M
Basic Shares Outstanding	5M	5.11M	11.22M	11.22M	10.27M	11.99M	16.13M	17.93M	17.98M	19.94M
Dividend Payout Ratio	-	-	-	-	-	-	-	-	-	-

Balance Sheet

	Dec 2015	Dec 2016	Dec 2017	Dec 2018	Dec 2019	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024
Total Current Assets+	11.88K	451.61K	1.9M	849.34K	7.76M	23.99M	82.61M	64.67M	39.94M	22.66M
Cash & Short-Term Investments	11.88K	141.66K	1.37M	186.2K	7M	21.97M	74.81M	52.15M	35.85M	20.92M
Cash Only	11.88K	141.66K	1.37M	186.2K	7M	21.97M	74.81M	52.15M	35.85M	20.92M
Short-Term Investments	0	0	0	0	0	0	0	0	0	0
Accounts Receivable	0	0	327.61K	647.59K	645.36K	0	5.5M	8.46M	2.44M	1.41M
Days Sales Outstanding	-	-	-	-	-	-	11.1K	8.26K	5.75K	36.73K
Inventory	0	0	0	0	-769.13M	0	-5.5M	34K	0	0
Days Inventory Outstanding	-	-	-	-	-	-	-	-	-	-
Other Current Assets	0	306.95K	0	0	769.13M	1.8M	5.5M	-34K	0	331K
Total Non-Current Assets+	0	0	16.51M	16.51M	16.71M	16.67M	17.34M	17.12M	17.06M	16.9M
Property, Plant & Equipment	0	0	0	0	191.54K	156K	726K	507K	414K	307K
Fixed Asset Turnover	-	-	-	-	-	0.07x	0.25x	0.74x	0.37x	0.05x
Goodwill	0	0	0	0	0	0	0	0	0	0
Intangible Assets	0	0	16.51M	16.51M	16.51M	16.51M	16.51M	16.51M	16.51M	16.51M
Long-Term Investments	0	0	0	0	0	0	0	0	0	0
Other Non-Current Assets	0	0	0	0	0	0	99K	99K	131K	79K
Total Assets+	11.88K	451.61K	18.41M	17.36M	24.47M	40.66M	99.94M	81.8M	57M	39.56M
Asset Turnover	-	-	-	-	-	0.00x	0.00x	0.00x	0.00x	0.00x
Asset Growth %	-	37.01%	39.77%	-0.06%	0.41%	0.66%	1.46%	-0.18%	-0.3%	-0.31%
Total Current Liabilities+	30.75K	600.81K	309.72K	823.77K	700.38K	1.78M	4.36M	10.92M	18.46M	7.22M
Accounts Payable	750	220.81K	136.4K	553.22K	401.99K	1.52M	3.8M	5.21M	7.9M	6.56M
Days Payables Outstanding	-	-	-	-	-	-	-	-	-	-
Short-Term Debt	0	350K	0	0	0	0	72K	5M	9.92M	0
Deferred Revenue (Current)	0	0	0	0	-298.39K	0	474K	616K	0	0
Other Current Liabilities	30K	30K	0	0	298.39K	190K	-62K	9K	524K	517K
Current Ratio	0.39x	0.75x	6.13x	1.03x	11.09x	13.51x	18.95x	5.92x	2.16x	3.14x
Quick Ratio	0.39x	0.75x	6.13x	1.03x	1109.25x	13.51x	20.21x	5.92x	2.16x	3.14x
Cash Conversion Cycle	-	-	-	-	-	-	-	-	-	-
Total Non-Current Liabilities+	0	0	0	0	160.16K	126K	15.36M	10.77M	397K	244K
Long-Term Debt	0	0	0	0	0	0	14.46M	9.7M	0	0
Capital Lease Obligations	0	0	0	0	160.16K	126K	704K	526K	397K	244K
Deferred Tax Liabilities	0	0	0	0	0	0	0	0	0	0
Other Non-Current Liabilities	0	0	0	0	0	0	199K	550K	0	0
Total Liabilities	30.75K	600.81K	309.72K	823.77K	860.54K	1.9M	19.72M	21.69M	18.86M	7.46M
Total Debt+	0	350K	0	0	168.45K	160K	15.23M	15.31M	10.44M	384K
Net Debt	-11.88K	208.34K	-1.37M	-186.2K	-6.83M	-21.81M	-59.58M	-36.84M	-25.41M	-20.54M
Debt / Equity	-	-	-	-	0.01x	0.00x	0.19x	0.25x	0.27x	0.01x
Debt / EBITDA	-	712.83x	-	-	-	-	-	-	-	-
Net Debt / EBITDA	-0.08x	424.32x	-2855.65x	-	-	-	-	-	-	-
Interest Coverage	-	-	-	-	-	-	-	-19.25x	-	-
Total Equity+	-18.87K	-149.2K	18.1M	16.54M	23.61M	38.75M	80.22M	60.1M	38.14M	32.1M
Equity Growth %	-	-6.91%	122.34%	-0.09%	0.43%	0.64%	1.07%	-0.25%	-0.37%	-0.16%
Book Value per Share	-0.00	-0.03	1.61	1.47	2.30	3.23	4.97	3.35	2.12	1.61
Total Shareholders' Equity	-18.87K	-149.2K	18.1M	16.54M	23.61M	38.75M	80.22M	60.1M	38.14M	32.1M
Common Stock	5K	5.07K	8.32K	8.72K	10.77K	13K	18K	18K	817K	22K
Retained Earnings	-48.87K	-326.36K	-1.16M	-13.6M	-21.28M	-33.38M	-63.72M	-91.01M	-121.02M	-163.1M
Treasury Stock	0	0	0	0	0	0	0	0	0	0
Accumulated OCI	0	47.16K	32.04K	6.53K	-8.52K	11K	1K	-699K	-799K	-575K
Minority Interest	0	0	0	0	0	0	0	0	0	0

Cash Flow

	Dec 2015	Dec 2016	Dec 2017	Dec 2018	Dec 2019	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024
Cash from Operations+	-18.12K	-317.38K	-761.83K	-2.06M	-5.38M	-8.94M	-28.5M	-22.69M	-11.98M	-33.36M
Operating CF Margin %	-	-	-	-	-	-813.06%	-157.48%	-60.66%	-77.29%	-2382.93%
Operating CF Growth %	-	-16.52%	-1.4%	-1.7%	-1.62%	-0.66%	-2.19%	0.2%	0.47%	-1.78%
Net Income	-48.87K	-277.49K	-831.49K	-12.44M	-7.68M	-12.1M	-30.34M	-27.3M	-30.01M	-42.08M
Depreciation & Amortization	0	0	0	0	0	0	0	0	0	0
Stock-Based Compensation	120K	0	199.56K	10M	4.1M	0	4.8M	7.15M	7.37M	7.61M
Deferred Taxes	0	0	0	0	0	0	0	0	0	0
Other Non-Cash Items	30K	50K	-150K	9.81M	-1.54M	3.11M	126K	328K	224K	79K
Working Capital Changes	750	-89.89K	20.1K	379.67K	-260.88K	43.51K	-3.09M	-2.86M	10.44M	1.04M
Change in Receivables	0	-260.49K	-67.12K	-319.98K	2.22K	-1.15M	-3.71M	-2.96M	6.02M	1.03M
Change in Inventory	0	0	0	0	-2.22K	0	3.71M	2.96M	0	0
Change in Payables	0	220.06K	238.91K	514.05K	-131.68K	1.08M	2.26M	1.4M	2.72M	-1.37M
Cash from Investing+	0	0	-100K	0	0	0	-15M	0	0	0
Capital Expenditures	0	0	-100K	0	0	0	-15M	0	0	0
CapEx % of Revenue	-	-	-	-	-	0%	82.87%	-	-	-
Acquisitions	-	-	-	-	-	-	-	-	-	-
Investments	-	-	-	-	-	-	-	-	-	-
Other Investing	0	0	-100K	0	0	0	0	0	0	0
Cash from Financing+	30K	450K	2.06M	900K	12.21M	23.9M	96.36M	729K	-4.22M	18.21M
Debt Issued (Net)	-	-	-	-	-	-	-	-	-	-
Equity Issued (Net)	-	-	-	-	-	-	-	-	-	-
Dividends Paid	0	0	0	0	0	0	0	0	0	0
Share Repurchases	-	-	-	-	-	-	-	-	-	-
Other Financing	120K	0	0	0	0	0	1.15M	30K	0	422K
Net Change in Cash	-	-	-	-	-	-	-	-	-	-
Free Cash Flow+	-18.12K	-317.38K	-861.83K	-2.06M	-5.38M	-8.94M	-43.5M	-22.69M	-11.98M	-33.36M
FCF Margin %	-	-	-	-	-	-813.06%	-240.35%	-60.66%	-77.29%	-2382.93%
FCF Growth %	-	-16.52%	-1.72%	-1.39%	-1.62%	-0.66%	-3.86%	0.48%	0.47%	-1.78%
FCF per Share	-0.00	-0.06	-0.08	-0.18	-0.52	-0.75	-2.70	-1.27	-0.67	-1.67
FCF Conversion (FCF/Net Income)	0.37x	1.15x	0.92x	0.17x	0.70x	0.74x	0.94x	0.83x	0.40x	0.79x
Interest Paid	0	0	0	0	0	0	0	0	0	0
Taxes Paid	0	0	0	0	0	0	0	0	0	0

Key Ratios

Metric	2015	2016	2017	2018	2019	2020	2021	2022	2023	2024
Return on Equity (ROE)	-	-	-9.26%	-71.82%	-38.25%	-38.8%	-51%	-38.91%	-61.09%	-119.83%
Return on Invested Capital (ROIC)	-	-1199.45%	-8.76%	-56.4%	-35.11%	-54.38%	-116.31%	-88.65%	-123.96%	-263.32%
Gross Margin	-	-	-	-	-	100%	100%	100%	100%	100%
Net Margin	-	-	-	-	-	-109990.91%	-16762.43%	-7299.2%	-19360%	-300585.71%
Debt / Equity	-	-	-	-	0.01x	0.00x	0.19x	0.25x	0.27x	0.01x
Interest Coverage	-	-	-	-	-	-	-	-19.25x	-	-
FCF Conversion	0.37x	1.15x	0.92x	0.17x	0.70x	0.74x	0.94x	0.83x	0.40x	0.79x
Revenue Growth	-	-	-	-	-	-	1545.45%	106.63%	-58.56%	-90.97%

Frequently Asked Questions

Growth & Financials

INmune Bio, Inc. (INMB) reported $0.1M in revenue for fiscal year 2024.

INmune Bio, Inc. (INMB) saw revenue decline by 91.0% over the past year.

INmune Bio, Inc. (INMB) reported a net loss of $49.9M for fiscal year 2024.

Dividend & Returns

INmune Bio, Inc. (INMB) has a return on equity (ROE) of -119.8%. Negative ROE indicates the company is unprofitable.

INmune Bio, Inc. (INMB) had negative free cash flow of $31.5M in fiscal year 2024, likely due to heavy capital investments.

US Stock Screener

...

INmune Bio, Inc. (INMB) 10-Year Financial Performance & Capital Metrics

INMB • • Industrial / General

HealthcareBiotechnologyOncology TherapeuticsImmuno-Oncology

Revenue $14K -91.0%
EBITDA -$42M
Net Income -$42M -40.2%
EPS (Diluted) -2.11 -26.3%
Gross Margin 100%
EBITDA Margin -300585.71%
Operating Margin -304535.71% -1487.1%
Net Margin -300585.71% -1452.6%
ROE -119.83% -96.2%
ROIC -263.32% -112.4%
Debt/Equity 0.01 -95.6%
Interest Coverage -

Technical Analysis

Key Insights

Based on financial data analysis

✓Strengths

✓Company is almost debt free
✓Trading at only 1.0x book value

✗Weaknesses

✗Weak Piotroski F-Score: 3/9
✗Negative free cash flow
✗Weak momentum: RS Rating 11 (bottom 11%)
✗Shares diluted 10.9% in last year
✗Trading more than 30% below 52-week high
✗Low asset turnover indicates capital-intensive operations

Price & Volume

Loading chart...

Growth Metrics

Revenue CAGR

10Y-

5Y-

3Y-57.39%

TTM19.05%

Profit (Net Income) CAGR

10Y-

5Y-

3Y-

TTM-20.87%

EPS CAGR

10Y-

5Y-

3Y-

TTM2.29%

ROCE

10Y Avg-178.77%

5Y Avg-57.65%

3Y Avg-68.62%

Latest-120.31%

Peer Comparison

Immuno-Oncology

Name	Market Cap	Current Price	P/E Ratio	Revenue Growth 1Y	Net Margin	ROE	Debt/Equity
IMTXImmatics N.V.	1.33B	9.92	70.86	188.6%	-136.72%	-27.81%	0.03
CTMXCytomX Therapeutics, Inc.	720.1M	4.25	11.18	36.45%	24.66%	26.09%
IOVAIovance Biotherapeutics, Inc.	881.27M	2.22	-1.73	136.99%	-158.78%	-56.62%	0.08
REPLReplimune Group, Inc.	572.64M	7.30	-2.38			-117.82%	0.18
NKTRNektar Therapeutics	719.28M	35.36	-4.07	9.22%	-192.87%	-141.9%	1.69
IMNMImmunome, Inc.	2.52B	22.85	-4.57	-35.5%	-23.01%	-84.4%	0.03
IBRXImmunityBio, Inc.	3.89B	3.95	-6.37	22.71%	-422.28%
NRIXNurix Therapeutics, Inc.	1.91B	18.86	-6.55	-29.15%	-292.5%	-65.76%	0.05

Profit & Loss

	Dec 2015	Dec 2016	Dec 2017	Dec 2018	Dec 2019	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024
Sales/Revenue+	0	0	0	0	0	11K	181K	374K	155K	14K
Revenue Growth %	-	-	-	-	-	-	15.45%	1.07%	-0.59%	-0.91%
Cost of Goods Sold+	0	0	0	0	0	0	0	0	0	0
COGS % of Revenue	-	-	-	-	-	-	-	-	-	-
Gross Profit+	0	0	0	0	0	11K	181K	374K	155K	14K
Gross Margin %	-	-	-	-	-	1%	1%	1%	1%	1%
Gross Profit Growth %	-	-	-	-	-	-	15.45%	1.07%	-0.59%	-0.91%
Operating Expenses+	48.87K	227.49K	981.48K	12.44M	7.76M	12.24M	29.33M	26.32M	29.9M	42.65M
OpEx % of Revenue	-	-	-	-	-	1112.64%	162.07%	70.39%	192.88%	3046.36%
Selling, General & Admin	48.87K	126K	546.12K	9.09M	4.47M	6.32M	8.79M	9.26M	9.62M	9.48M
SG&A % of Revenue	-	-	-	-	-	574.64%	48.57%	24.75%	62.08%	677.36%
Research & Development	0	101.5K	435.36K	1.1M	3.28M	5.92M	20.54M	17.07M	20.27M	33.17M
R&D % of Revenue	-	-	-	-	-	537.91%	113.5%	45.63%	130.79%	2369%
Other Operating Expenses	0	0	-6	0	0	1K	0	0	0	0
Operating Income+	-48.87K	-227K	-981K	-12.44M	-7.76M	-12.23M	-29.15M	-25.95M	-29.74M	-42.63M
Operating Margin %	-	-	-	-	-	-1111.64%	-161.07%	-69.39%	-191.88%	-3045.36%
Operating Income Growth %	-	-3.65%	-3.32%	-11.68%	0.38%	-0.58%	-1.38%	0.11%	-0.15%	-0.43%
EBITDA+	146.6K	491	480	0	-7.68M	0	0	0	0	-42.08M
EBITDA Margin %	-	-	-	-	-	-	-	-	-	-3005.86%
EBITDA Growth %	-	-1%	-0.02%	-1%	-	1%	-	-	-	-
D&A (Non-Cash Add-back)	195.47K	227.49K	981.48K	12.44M	0	12.23M	29.15M	25.95M	29.74M	553K
EBIT	-48.87K	-277K	-831K	-12.44M	-7.68M	-12.23M	-29.15M	-25.95M	-29.74M	-42.63M
Net Interest Income+	0	0	0	0	77.69K	0	0	-2.01M	0	0
Interest Income	0	0	0	0	77.69K	0	0	0	0	0
Interest Expense	0	0	0	0	0	0	0	1.35M	0	0
Other Income/Expense	0	-50K	149.99K	0	77.69K	129K	-1.19M	-1.35M	-267K	553K
Pretax Income+	-48.87K	-277K	-831K	-12.44M	-7.68M	-12.1M	-30.34M	-27.3M	-30.01M	-42.08M
Pretax Margin %	-	-	-	-	-	-1099.91%	-167.62%	-72.99%	-193.6%	-3005.86%
Income Tax+	0	0	0	0	0	0	0	0	0	0
Effective Tax Rate %	1%	1%	1%	1%	1%	1%	1%	1%	1%	1%
Net Income+	-48.87K	-277K	-831K	-12.44M	-7.68M	-12.1M	-30.34M	-27.3M	-30.01M	-42.08M
Net Margin %	-	-	-	-	-	-1099.91%	-167.62%	-72.99%	-193.6%	-3005.86%
Net Income Growth %	-	-4.67%	-2%	-13.97%	0.38%	-0.58%	-1.51%	0.1%	-0.1%	-0.4%
Net Income (Continuing)	-48.87K	-277K	-831K	-12.44M	-7.68M	-12.1M	-30.34M	-27.3M	-30.01M	-42.08M
Discontinued Operations	0	0	0	0	0	0	0	0	0	0
Minority Interest	0	0	0	0	0	0	0	0	0	0
EPS (Diluted)+	-0.01	-0.05	-0.07	-1.11	-0.89	-1.01	-1.88	-1.52	-1.67	-2.11
EPS Growth %	-	-	-0.37%	-13.98%	0.2%	-0.13%	-0.86%	0.19%	-0.1%	-0.26%
EPS (Basic)	-0.01	-0.05	-0.07	-1.11	-0.89	-1.01	-1.88	-1.52	-1.67	-2.11
Diluted Shares Outstanding	5M	5.11M	11.22M	11.22M	10.27M	11.99M	16.13M	17.93M	17.98M	19.94M
Basic Shares Outstanding	5M	5.11M	11.22M	11.22M	10.27M	11.99M	16.13M	17.93M	17.98M	19.94M
Dividend Payout Ratio	-	-	-	-	-	-	-	-	-	-

Balance Sheet

	Dec 2015	Dec 2016	Dec 2017	Dec 2018	Dec 2019	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024
Total Current Assets+	11.88K	451.61K	1.9M	849.34K	7.76M	23.99M	82.61M	64.67M	39.94M	22.66M
Cash & Short-Term Investments	11.88K	141.66K	1.37M	186.2K	7M	21.97M	74.81M	52.15M	35.85M	20.92M
Cash Only	11.88K	141.66K	1.37M	186.2K	7M	21.97M	74.81M	52.15M	35.85M	20.92M
Short-Term Investments	0	0	0	0	0	0	0	0	0	0
Accounts Receivable	0	0	327.61K	647.59K	645.36K	0	5.5M	8.46M	2.44M	1.41M
Days Sales Outstanding	-	-	-	-	-	-	11.1K	8.26K	5.75K	36.73K
Inventory	0	0	0	0	-769.13M	0	-5.5M	34K	0	0
Days Inventory Outstanding	-	-	-	-	-	-	-	-	-	-
Other Current Assets	0	306.95K	0	0	769.13M	1.8M	5.5M	-34K	0	331K
Total Non-Current Assets+	0	0	16.51M	16.51M	16.71M	16.67M	17.34M	17.12M	17.06M	16.9M
Property, Plant & Equipment	0	0	0	0	191.54K	156K	726K	507K	414K	307K
Fixed Asset Turnover	-	-	-	-	-	0.07x	0.25x	0.74x	0.37x	0.05x
Goodwill	0	0	0	0	0	0	0	0	0	0
Intangible Assets	0	0	16.51M	16.51M	16.51M	16.51M	16.51M	16.51M	16.51M	16.51M
Long-Term Investments	0	0	0	0	0	0	0	0	0	0
Other Non-Current Assets	0	0	0	0	0	0	99K	99K	131K	79K
Total Assets+	11.88K	451.61K	18.41M	17.36M	24.47M	40.66M	99.94M	81.8M	57M	39.56M
Asset Turnover	-	-	-	-	-	0.00x	0.00x	0.00x	0.00x	0.00x
Asset Growth %	-	37.01%	39.77%	-0.06%	0.41%	0.66%	1.46%	-0.18%	-0.3%	-0.31%
Total Current Liabilities+	30.75K	600.81K	309.72K	823.77K	700.38K	1.78M	4.36M	10.92M	18.46M	7.22M
Accounts Payable	750	220.81K	136.4K	553.22K	401.99K	1.52M	3.8M	5.21M	7.9M	6.56M
Days Payables Outstanding	-	-	-	-	-	-	-	-	-	-
Short-Term Debt	0	350K	0	0	0	0	72K	5M	9.92M	0
Deferred Revenue (Current)	0	0	0	0	-298.39K	0	474K	616K	0	0
Other Current Liabilities	30K	30K	0	0	298.39K	190K	-62K	9K	524K	517K
Current Ratio	0.39x	0.75x	6.13x	1.03x	11.09x	13.51x	18.95x	5.92x	2.16x	3.14x
Quick Ratio	0.39x	0.75x	6.13x	1.03x	1109.25x	13.51x	20.21x	5.92x	2.16x	3.14x
Cash Conversion Cycle	-	-	-	-	-	-	-	-	-	-
Total Non-Current Liabilities+	0	0	0	0	160.16K	126K	15.36M	10.77M	397K	244K
Long-Term Debt	0	0	0	0	0	0	14.46M	9.7M	0	0
Capital Lease Obligations	0	0	0	0	160.16K	126K	704K	526K	397K	244K
Deferred Tax Liabilities	0	0	0	0	0	0	0	0	0	0
Other Non-Current Liabilities	0	0	0	0	0	0	199K	550K	0	0
Total Liabilities	30.75K	600.81K	309.72K	823.77K	860.54K	1.9M	19.72M	21.69M	18.86M	7.46M
Total Debt+	0	350K	0	0	168.45K	160K	15.23M	15.31M	10.44M	384K
Net Debt	-11.88K	208.34K	-1.37M	-186.2K	-6.83M	-21.81M	-59.58M	-36.84M	-25.41M	-20.54M
Debt / Equity	-	-	-	-	0.01x	0.00x	0.19x	0.25x	0.27x	0.01x
Debt / EBITDA	-	712.83x	-	-	-	-	-	-	-	-
Net Debt / EBITDA	-0.08x	424.32x	-2855.65x	-	-	-	-	-	-	-
Interest Coverage	-	-	-	-	-	-	-	-19.25x	-	-
Total Equity+	-18.87K	-149.2K	18.1M	16.54M	23.61M	38.75M	80.22M	60.1M	38.14M	32.1M
Equity Growth %	-	-6.91%	122.34%	-0.09%	0.43%	0.64%	1.07%	-0.25%	-0.37%	-0.16%
Book Value per Share	-0.00	-0.03	1.61	1.47	2.30	3.23	4.97	3.35	2.12	1.61
Total Shareholders' Equity	-18.87K	-149.2K	18.1M	16.54M	23.61M	38.75M	80.22M	60.1M	38.14M	32.1M
Common Stock	5K	5.07K	8.32K	8.72K	10.77K	13K	18K	18K	817K	22K
Retained Earnings	-48.87K	-326.36K	-1.16M	-13.6M	-21.28M	-33.38M	-63.72M	-91.01M	-121.02M	-163.1M
Treasury Stock	0	0	0	0	0	0	0	0	0	0
Accumulated OCI	0	47.16K	32.04K	6.53K	-8.52K	11K	1K	-699K	-799K	-575K
Minority Interest	0	0	0	0	0	0	0	0	0	0

Cash Flow

	Dec 2015	Dec 2016	Dec 2017	Dec 2018	Dec 2019	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024
Cash from Operations+	-18.12K	-317.38K	-761.83K	-2.06M	-5.38M	-8.94M	-28.5M	-22.69M	-11.98M	-33.36M
Operating CF Margin %	-	-	-	-	-	-813.06%	-157.48%	-60.66%	-77.29%	-2382.93%
Operating CF Growth %	-	-16.52%	-1.4%	-1.7%	-1.62%	-0.66%	-2.19%	0.2%	0.47%	-1.78%
Net Income	-48.87K	-277.49K	-831.49K	-12.44M	-7.68M	-12.1M	-30.34M	-27.3M	-30.01M	-42.08M
Depreciation & Amortization	0	0	0	0	0	0	0	0	0	0
Stock-Based Compensation	120K	0	199.56K	10M	4.1M	0	4.8M	7.15M	7.37M	7.61M
Deferred Taxes	0	0	0	0	0	0	0	0	0	0
Other Non-Cash Items	30K	50K	-150K	9.81M	-1.54M	3.11M	126K	328K	224K	79K
Working Capital Changes	750	-89.89K	20.1K	379.67K	-260.88K	43.51K	-3.09M	-2.86M	10.44M	1.04M
Change in Receivables	0	-260.49K	-67.12K	-319.98K	2.22K	-1.15M	-3.71M	-2.96M	6.02M	1.03M
Change in Inventory	0	0	0	0	-2.22K	0	3.71M	2.96M	0	0
Change in Payables	0	220.06K	238.91K	514.05K	-131.68K	1.08M	2.26M	1.4M	2.72M	-1.37M
Cash from Investing+	0	0	-100K	0	0	0	-15M	0	0	0
Capital Expenditures	0	0	-100K	0	0	0	-15M	0	0	0
CapEx % of Revenue	-	-	-	-	-	0%	82.87%	-	-	-
Acquisitions	-	-	-	-	-	-	-	-	-	-
Investments	-	-	-	-	-	-	-	-	-	-
Other Investing	0	0	-100K	0	0	0	0	0	0	0
Cash from Financing+	30K	450K	2.06M	900K	12.21M	23.9M	96.36M	729K	-4.22M	18.21M
Debt Issued (Net)	-	-	-	-	-	-	-	-	-	-
Equity Issued (Net)	-	-	-	-	-	-	-	-	-	-
Dividends Paid	0	0	0	0	0	0	0	0	0	0
Share Repurchases	-	-	-	-	-	-	-	-	-	-
Other Financing	120K	0	0	0	0	0	1.15M	30K	0	422K
Net Change in Cash	-	-	-	-	-	-	-	-	-	-
Free Cash Flow+	-18.12K	-317.38K	-861.83K	-2.06M	-5.38M	-8.94M	-43.5M	-22.69M	-11.98M	-33.36M
FCF Margin %	-	-	-	-	-	-813.06%	-240.35%	-60.66%	-77.29%	-2382.93%
FCF Growth %	-	-16.52%	-1.72%	-1.39%	-1.62%	-0.66%	-3.86%	0.48%	0.47%	-1.78%
FCF per Share	-0.00	-0.06	-0.08	-0.18	-0.52	-0.75	-2.70	-1.27	-0.67	-1.67
FCF Conversion (FCF/Net Income)	0.37x	1.15x	0.92x	0.17x	0.70x	0.74x	0.94x	0.83x	0.40x	0.79x
Interest Paid	0	0	0	0	0	0	0	0	0	0
Taxes Paid	0	0	0	0	0	0	0	0	0	0

Key Ratios

Metric	2015	2016	2017	2018	2019	2020	2021	2022	2023	2024
Return on Equity (ROE)	-	-	-9.26%	-71.82%	-38.25%	-38.8%	-51%	-38.91%	-61.09%	-119.83%
Return on Invested Capital (ROIC)	-	-1199.45%	-8.76%	-56.4%	-35.11%	-54.38%	-116.31%	-88.65%	-123.96%	-263.32%
Gross Margin	-	-	-	-	-	100%	100%	100%	100%	100%
Net Margin	-	-	-	-	-	-109990.91%	-16762.43%	-7299.2%	-19360%	-300585.71%
Debt / Equity	-	-	-	-	0.01x	0.00x	0.19x	0.25x	0.27x	0.01x
Interest Coverage	-	-	-	-	-	-	-	-19.25x	-	-
FCF Conversion	0.37x	1.15x	0.92x	0.17x	0.70x	0.74x	0.94x	0.83x	0.40x	0.79x
Revenue Growth	-	-	-	-	-	-	1545.45%	106.63%	-58.56%	-90.97%

Frequently Asked Questions

Growth & Financials

INmune Bio, Inc. (INMB) reported $0.1M in revenue for fiscal year 2024.

INmune Bio, Inc. (INMB) saw revenue decline by 91.0% over the past year.

INmune Bio, Inc. (INMB) reported a net loss of $49.9M for fiscal year 2024.

Dividend & Returns

INmune Bio, Inc. (INMB) has a return on equity (ROE) of -119.8%. Negative ROE indicates the company is unprofitable.

INmune Bio, Inc. (INMB) had negative free cash flow of $31.5M in fiscal year 2024, likely due to heavy capital investments.